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1 In-octreotide scintigraphy in patients with persistent medullary thyroid car-
cinoma (MTC) visualized tumors in about half of the surgically explored sites.
Tumor visualization correlated with rapid tumorgrowth and large tumorvolume
as judged from calcitonin levels. The 111In concentration ratio between tumor
(T) and blood (B) in surgically excised lymph node metastases ofMTC showed
a large variation, with low values for microscopic and high values for macro-
scopic metastases in individual patients. Three cases ofMTC, Hurthle cell ade-
noma and papillary thyroid cancer are reported with preoperative scintigraphy,
T/B ratios and Northern analyses of the surgical biopsies. Visualization of
tumors was possible in the absence of sstr2 (the high affinity receptor for
octreotide) with the exception of microscopic tumor growth. T/B values in the
patient with Hurthle cell adenoma were similar to those found in the contralat-
eral thyroid lobe with goitre. The relatively high uptake of III1n in benign thy-
roid conditions probably limits the use ofoctreotide scintigraphy in the diagno-
sis of primary tumors. The technique has certain advantages over radioiodine
scintigraphy after the surgical treatment of thyroid tumors: no need for with-
drawal of thyroxin substitution; a possibility to diagnose metastases of tumors
that do not concentrate radioiodine (MTC, Hurthle cell cancer); and comple-
mentary information about metastatic sites of non-medullary thyroid cancer
(papillary and follicular tumors).
INTRODUCTION
Neuroendocrine tumors, including medullary thyroid carcinoma (MTC)e, may
express somatostatin receptors (sstr). Somatostatin and its long-acting analogue,
octreotide, have been shown to inhibit incorporation of3H-thymidine into human thyroid
follicular cell lines indicating expression of sstr physiologically. Somatostatin inhibits
DNA synthesis induced by thyrotropin in such cell lines [1, 2]. However, after neoplastic
transformation, somatostatin analogues may induce proliferation as shown in differentiat-
ed human thyroid cancer cell lines [3]. In patients with MTC, the only effective treatment
today available is surgery [4]. In cases of differentiated non-MTC tumors, distant metas-
tases can be treated with radioiodine. Radioiodine can also be used to diagnose residual
thyroid cancer in the neck as well as distant metastases. However, one third of the non-
MTC tumors do not accumulate radioiodine [5]. One future aim will be to investigate
expression of sstr on various types ofthyroid tumors to be able to evaluate their uptake of
a radiolabelled somatostatin analogue, 111In-octreotide, for diagnostic and therapeutic
purposes.
a To whom all correspondence should be addressed:Ha.kan Ahlman, M.D., Professor ofEndocrine
Surgery, Department of Surgery, Sahlgrenska University Hospital, S-413 45 Goteborg, Sweden.
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MTC is a neuroendocrine tumor derived from thyroid C-cells. In patients with
MTC, basal and stimulated serum calcitonin concentrations are sensitive tumor markers
reflecting the tumor volume [6, 7]. Presence of lymph node metastases in MTC has a
more serious impact on survival than in papillary thyroid carcinoma [8]. One third ofthe
MTC patients with persistent, orrecurrent, disease afterprimary thyroidectomy can have
their calcitonin levels normalized after repeat meticulous neck operations with microdis-
section technique [4]. Complete work-up with ultrasound, CT, MR and bone scintigra-
phy has low sensitivity in the localization ofnew lesions [9]. The surgical results would
improve if good tumor localization methods were available. Selective catheterization
and calcitonin determinations can often localize tumors to a region, but not to a specif-
ic site. Scintigraphic methods utilizing 1231I or 13ll-MIBG, 201TI-chloride, 99mTc-V-
DMSA or radiolabeled monoclonal antibodies against calcitonin or carcinoembronic
antigen (CEA) have been oflimited value so far [10]. In a previous study, we found that
octreotide scintigraphy visualized large primary MTC tumors, but only half of the sur-
gically identified neck metastases [11].
In the present study, the IIIIn concentration ratios between tumor and blood (T/B)
were determined and compared with the findings at ll In-octreotide scintigraphy in three
different thyroid tumor forms (MTC, Hurthle cell adenoma and papillary thyroid cancer).
In these individual patients, Northern analyses of all five sstr subtypes were also per-
formed.
MATERIAL AND METHODS
Patients
Fifteen patients had previously been thyroidectomized for MTC. They were followed
with annual tests for serum concentrations ofcalcitonin and CEA. At the time ofthe pre-
sent investigation all patients had raised calcitonin concentrations indicating persistent
disease. Before repeat surgery, including meticulous lymph node dissection, they under-
went scintigraphy after injection of IIIn-DTPA-D-Phel-octreotide. After the operations,
the II1n concentration ratios were determined between freshly harvested lymph node
metastases and blood.
Three patients with different types of thyroid tumors were worked up in detail with
preoperative scintigraphy and determinations of T/B ratios and sstr subtypes: Patient A
had previously been subjected to thyroidectomy due to MTC and had persistent disease;
Patient B had a Hurthle cell adenoma in a nodular goitre; and patient C had a papillary
thyroid carcinoma with lymph node metastases.
Scintigraphy
The patients received 190-350 MBq l1I1n-DTPA-D-PheI octreotide (10-20 pg)
(Mallinckrodt, Petten, the Netherlands) by i.v. route. The amount of lllIn bound to
octreotide was higher than 98 percent. Imaging was done 24-48 hr after injection of the
radiopharmaceutical. A gamma camera (GE 400 AC/T), equipped with a medium energy
parallel hole collimator and connected to a GE STARCAM computer system, was used.
Data acquisition was done in a dual window setting (173 and 247 keV). Single photon
emission computed tomography (SPECT) was performed in all patients (see [12] for fur-
ther details).
The ratio between tumor (T) to background (Bg) uptake was calculated from preop-
erative scintigraphic images. A region ofinterest (ROI) was drawn over the tumor to esti-
mate the activity content ofthe tumor and the same ROI was used to estimate the activity
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content of the background (normal thyroid if present, otherwise tissue adjacent to the
tumor).
Calcitonin and CEA assays
Serum calcitonin was determined by a non-extraction immunoradiometric assay with
a detection limit of 2.4 ng/l (Medgenix, Fleurus, Belgium). The upper normal reference
limit after thyroidectomy was 20 ng/l. CEA was determined with an immunofluorometric
assay (Delfia, Turku, Finland) with a detection limit of 0.2 ,ug/l and upper normal refer-
ence limit of 5 pg/l.
Measurement ofIIIn concentration in tissue samples and blood
Before histopathological examination, the fresh surgical specimens and blood sam-
ples withdrawn during surgery were weighed, and the IIlIn concentration was measured
in a calibrated gamma counter equipped with a NaI(Tl) well crystal (diameter 7.6 cm,
length 7.6 cm, Harshaw, De Meern, Holland) and a single-channel pulse-height analyzer
(Elscint, Haifa, Israel). Corrections were made for background activity and radioactive
decay. Tissue-to-blood I1IIn concentration ratios, (Ti/B), were calculated as well as T/B
ratios, for all histology-proven biopsies [cf. 13].
Northern analyses ofsstrl-5 mRNA expression
Fresh tumor specimens were rapidly frozen in liquid nitrogen. RNA was prepared by
acid guanidine thiocyanate-phenol-chloroform extraction [14]. Samples oftotal RNA (20
,ug) were heat-denatured and electrophoresed in a one percent agarose gel with 2.2 mol/l
Table 1. l11n concentration between tumor and blood (T/B) in lymph node metastases of
medullary thyroid carcinoma at various time intervals after injection of1111n-DTPA-D-Phe1-
octreotide in 15 patients with persistent disease.
Time after Number of
injection Pat. no. T/B metastases
I day I 4-39 9
II 2*-41 10
2 days III 9 1
IV 4-33 6
V 17-47 5
5 days VI 15-18 4
VII 11-24 2
VIII 3-43 2
IX 36 1
X 4-13 3
XI 3*-240 9
6 days XII 2*-32 16
7 days XIII 3*-350 5
XIV 6-14 7
XV 27-34 2
* Microscopic tumor growth.
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formaldehyde, 1 mmol/l EDTA, 5 mmol/l sodium acetate and 20 mmol/l morpholine
propane sulphonic acid (pH 7.0) as running buffer. RNA was transferred to positively
charged nylon membranes (Boehringer, Mannheim, FRG) using a vacuum transfer system
(Hybaid, Middlesex, UK) and crosslinked to the membrane by UV-light (Stratalinker,
Stratagene, LaJolla, CA). Membranes were hybridized in rotating flasks at 65°C (Hybaid,
Middlesex, UK) using 32P-labelled antisense RNA probes. The following cRNA probes
were used:
1. A 1.126 bp PCR fragment of the human sstrl corresponding to
nucleotides 352-1478 [14].
2. A 1.7 kb Bam HI/Hind III cDNA fragment ofthe human sstr2 [15].
3. A 1.9 kb Nco I/Hind III cDNA fragment of the human sstr3 [16].
4. A 2.0 kb Nae I/Xba I cDNA fragment ofthe human sstr4 [17].
5. A 1.6 kb Eco RI/Sal II cDNA fragment of the human sstr5 [18].
Specific labelling was detected after three to six days exposure on an imaging plate,
followed by reading in a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA).
Figure 1. lllIn concentration ratio between tissue biopsies and blood (Ti/B), between tumor
and adjacent tissue from scintigraphy (T/Bg) and somatostatin receptor subtypes in patientA
with recurrent lymph node metastases in the neck after total thyroidectomy for MTC (cf. Pat
no IV in Table 1), two days after injection oflllln-DTPA-D-Phel-octreotide.
Histopathological Ti/B T/Bg Receptor
findings (biopsy) (scintigraphy) subtypes
Pos. lymph node 31
Pos. lymph node 32 } 1.2* sstp, sst45
Pos. lymph node 33
Neg. lymph node 3.8
Fat 5.7
* Bg, adjacent tissue.
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RESULTS
TIB ratios oflymph node metastases in patients withpersistent MTC
The T/B ratio for the lymph node metastases, excised at various time intervals (1-7
days) after injection of I111n-DTPA-D-Phel-octreotide in the 15 patients, showed a wide
intra- and interindividual variation (Table 1). In the entire material, the lowest T/B values
were seen in nodes with microscopic tumor growth. In four patients (I, II, XII and XIV),
TJB values were plotted against the weights of the dissected lymph nodes for each indi-
vidual patient. No significant correlation was demonstrated. Some patients had metastat-
ic lymph nodes with high T/B values beside nodes with microscopic growth and low T/B
values (Table 1). Patient no. XI had five out of nine nodes with T/B ratios exceeding 80.
The highest value of240 was seen in a medium-sized tumor. Patient no. XIII had three out
offive nodes with values exceeding 190. The highest value of 350 was seen in the small-
est tumor.
PatientA (persistent MTC)
Female, born 1957, with total thyroidectomy and neck dissection in 1987. During
1990-1993 she had three further neck operations due to fast growing recurrent tumors. In
1995, she again had increasing tumor markers. Before surgery, III1n-octreotide scintigra-
phy suggested the presence of right-sided lymph node metastases (Figure 1). Three
excised lymph node metastases with macroscopic tumor growth had five- to eight-fold
higherT/B ratios than normal lymph nodes, orfattissue samples. The ratio ofT/Bg uptake
calculated from the preoperative scintigraphic images was much lower than the T/B ratios
(Figure 1). Northern analyses ofa lymph node metastasis revealed expression ofall recep-
tor subtypes except sstr2 and sstr3 (Figure 4). Repeat surgery, guided by the scintigraphy,
resulted in a 70 percent reduction ofcalcitonin levels.
Patient B (Hiirthle cell adenoma)
Female, born 1925, with left-sided thyroid nodule. Fine needle biopsy suggested the
presence of a malignant tumor. Preoperative IIIIn-octreotide scintigraphy visualized the
entire thyroid gland with more intense uptake over the adenoma (Figure 2). The ratio of
TIBg uptake calculated from scintigraphy was lower with a thyroid background than with
a background of adjacent tissue. A total thyroidectomy was performed with lymph node
dissection. The histopathological examination demonstrated a Hurthle cell adenoma. The
remaining parts ofthe thyroid gland revealed a nodular goitre with areas of severe sclero-
sis. TheT/B ratio forthe adenoma was higherthan forthe pyramidal and contralateral thy-
roid lobe. The lymph nodes had much lower values and had a normal histological appear-
ance (Figure 2). Northern analyses ofthe adenoma revealed expression of all five recep-
tor subtypes except sstr2 (Figure 4).
Patient C (papillary thyroid carcinoma)
Male, born 1918, with bilateral thyroid tumors. Fine needle biopsy indicatedpapillary
thyroid carcinoma. Preoperative ll In-octreotide scintigraphy visualized bilateral uptakes
in the thyroid (Figure 3). The T/Bg ratio from scintigraphy did not reveal any differences
between the two tumors, while the T/B ratio for the left-sided lesion was twice as high as
for the right-sided lesion. A total thyroidectomy was performed with neck dissection. The
histopathological examination demonstrated bilateral papillary thyroid carcinoma as well
as a thyroid cyst. Of the lymph node metastases, one was clinically overt and three were
microscopic. Twelve lymph nodes were tumor-free. The T/B values for the tumor were
highei than the Ti/B value seen for normal thyroid tissue and for the thyroid cyst. The
lymph node with macroscopic growth had similar values as two of the three nodes with
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microscopic growth. These values were not significantly different from the tumor-free
nodes (Figure 3). Northern analysis of the papillary carcinoma revealed expression of all
five receptor subtypes except sstr2 (Figure 4).
DISCUSSION
In a previous study of MTC-patients [11] with biochemically proven persistent dis-
ease, l IlIn-octreotide scintigraphy visualized lymph node metastases in about half of the
patients in accordance with other investigators [10, 19]. These patients had significantly
higher basal concentrations of serum calcitonin and CEA indicating larger tumor volume.
This finding was confirmed by morphometric studies of lymph node metastases.
Kwekkeboom et al. [20] had previously shown that small MTC tumors, although express-
ing sstr shown by autoradiography, were not always visualized scintigraphically. They
could not decide whether this was due to small size ofthe lesion or to low density of sstr,
or both. The growth rate of MTC can be monitored by measuring the increase of serum
calcitonin with time [7, 21]. There is an evident relation between the increment ofplasma
calcitonin and bad prognosis and tumor recurrence [21]. In our own series, the annual
increment of basal calcitonin levels was much higher in patients with scintigraphically
positive tumors. This finding could be due to large tumor volume and/or expression of sstr
in the rapidly growing tumors. In our series, tumor-associated symptoms and mortality
Figure 2. l1lIn concentration ratio between tissue biopsies and blood (Ti/B), between tumor
and adjacent tissue from scintigraphy (t/bg) and somatostatin receptor subtypes for patient B
with unilateral Hiirthle cell adenoma in nodular goitre, five days after injection of ll1In-
DTPA-D-Phet-octreotide.
Histopathological Ti/B T/Bg Receptor
findings (biopsy) (scintigraphy) subtypes
Primary tumor (sin) 45 1.7* sst1, sst35 3.435
Contralat. lobe (dx) 32
Pyramidal lobe 34
Neg. lymph nodes 2-13 (n = 23)
* Bg, thyroid
** Adjacent tissue
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during the period of follow-up occurred only in patients with positive 1Illn-octreotide
scintigraphy [11]. These results are in contrast to the study performed by Kwekkeboom et
al. [20], in which the ratio between basal serum calcitonin and CEA concentrations were
high in patients with positive imaging. They interpreted this finding that well-differentiat-
ed tumors expressed sstr, especially since one MTC tumor, previously studied in several
tumoral regions by autoradiography, seemed to express sstr in the more differentiated
parts.
In a previous study, we studied T/B ratios in several different scintigraphy-positive
neuroendocrine tumors with large variations between tumor types: low values forMTC (3-
39), high values for carcinoid tumors (27-650) and sometimes very high values for
endocrine pancreatic tumors (910-1500) [13, 22]. The T/B ratio seemed to be little influ-
enced by the time interval between injection of IlIn-octreotide and surgery. This indicates
Figure 3. l1lln concentration ratio between tissue biopsies and blood (Ti/B), between tumor
and adjacent tissue from scintigraphy (t/bg) and somatostatin receptor subtypes for patient C
with bilateral papillary thyroid carcinoma with lymph node metastases, five days after injec-
tion oflllIn-DTPA-D-Phel-octreotide.
Histopathological Ti/B T/Bg Receptor
findings (biopsy) (scintigraphy) subtypes
Primary tumor sin 54 2.5** sstl, sst
Primary tumor dx 27 2.7** 35
Pos. lymph node 10
Pos. lymph node 10*
Pos. lymph node 9*
Pos. lymph node 1.4*
Normal lobe sin 10
Thyroid cyst 6
Normal lobe dx 10
Neg. lymph nodes 4,4,4,7,7,7,8,8,10,15,16,22 (n = 12)
Fat 1.2
* Microscopic tumor growth.
** Bg, thyroid.
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similar pharmacokinetics II1n in tumor and non-tumor tissues, including blood, after the
initial uptake phase [23]. In some studies using radiolabelled monoclonal antibodies on
experimental tumors, a declining T/B ratio has been shown with increasing tumor size
[24]. These findings have not been corroborated in patients with neuroendocrine tumors
receiving IIIIn-DTPA-D-PheI-octreotide [13], orin the presentpatients with MTC. Part of
the discrepancy in T/B between carcinoids and MTC may be due to lower tumor volumes
in MTC, where early recurrence is diagnosed by sensitive biochemical methods. Otherfac-
tors may be different proportions oftumor cells in the biopsies, and variable expression of
Patient A I U
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Figure 4. Northern blot analyses ofsstrl-5 in tumor material from three patients: Medullary
thyroid carcinoma (A), Htirthle cell adenoma (B) and papillary thyroid cancer (C). All patients
lacked expression ofsstr2, and patientA also lacked expression ofsstr3. 18 S ribosomal bands serve
as controls.
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different sstr subtypes. These factors may also explain the discrepancy between patients
and between tumor tissues from individual patients with MTC (Table 1). Octreotide has
the highest binding affinity for sstr2, followed by sstr5 [25]. In patients, A-C sstr2 was not
revealed by Northern analysis, even though the tumors were scintigraphically visualized
most likely due to expression other sstr. PatientA also lacked expression ofsstr3. No quan-
titative studies on receptor densities for these tumors are available.
In a previous study of 21 non-medullary thyroid cancers (papillary, follicular and
anaplastic), IllIn-octreotide scintigraphy visualized specific uptakes in all patients with
primary tumors and in 75 percent of the metastatic lesions. The examination had a com-
plementary value to radioiodine scintigraphy, especially in the detection ofskeletal metas-
tases, while radio-iodine seemed to be superior in detecting pulmonary metastases. No
obvious difference in sensitivity occurred between follicular and papillary tumor types.
After withdrawal of thyroxine in preparation for radioiodine scintigraphy, the uptake of
lllln-octreotide appeared to be increased, possibly indicating sstr-upregulation by thy-
rotropin [26].
The clinical value of octreotide scintigraphy in patients with recurrent MTC is its
potential for tumor localization. This can be ofimportance in patients, who have been sub-
jected to several neck exploration with severe scar tissue formation. In these patients,
directed surgical explorations can be of substantial value (cf. Patient A). However, it is
important to bear in mind that only half of the surgically found metastases were visual-
ized in the receptor-positive patients [10, 11], which means that the surgical exploration
should be extended beyond the visualized sites. Visualization of lymph node metastases
may also serve as an indicator of worse prognosis [11].
Hurthle cell adenoma/carcinoma are thyroid tumors that cannot be visualized by
1311- or 99mTc scintigraphy. In our consecutive series of such patients (n = 6), both pri-
mary tumors and metastases were well demonstrated by Illln-DTPA-D-Phel-octreotide.
Patient B had a Hurthle cell adenoma in a nodular goitre, which illustrates a differential
diagnostic problem. The Ti/B values of the goitre tissue approached that of the adenoma
and was much higher than those seen in normal lymph nodes (Figure 2). The Ti/B values
for the goitre tissue was much higher than that seen for normal thyroid tissue in patient C,
also injected five days before surgery. The high uptake of II11n into the goitre tissue may
represent cellular uptake not only into thyroid follicular cells, but also into lymphocytes
infiltrating the sclerotic parts of the gland. A similar uptake of lllln in the thyroid in
benign conditions (endemic goitre, thyroid autonomy and Graves' disease) has been
reported previously [27]. The clinical management of this patient was not influenced by
preoperative imaging studies.
There are only preliminary observations available on imaging by I1In-DTPA-D-
Phe1-octreotide in patients with thyroid carcinoma. Patient C with papillary thyroid can-
cer displayed intense uptake in the thyroid tumors (Figure 3). No lymph node metastases
were visualized. The T/B values of tumor tissue were three to five times higher than the
Ti/B values ofnormal thyroid tissue. However, the T/B values ofmacroscopic and micro-
scopic lymph node metastases did not differ from the tumor-free nodes. The clinical man-
agement of this patient was not influenced by preoperative imaging.
Benign and malignant thyroid tumors and colloid goitre had increased uptakes of
IIIn as indicated by 1 lIn-octreotide scintigraphy and by increased T/B ratios. Therefore,
II In-octreotide scintigraphy will probably be oflimited value in diagnosing primary thy-
roid tumors. In that respect, lllln-octreotide scintigraphy will have a similar role as
radioiodine scintigraphy, i.e., they are most important after thyroidectomy to diagnose
residual neck tumor and distant metastases. Octreotide scintigraphy has three evident
advantages:
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1. Thyroid substitution therapy does not have to be withdrawn before
scintigraphy.
2. Metastases from Hurthle cell cancer and MTC can be visualized (i.e.
tumor types that do not concentrate radioiodine) [10, 11, 28, 29].
3. Ithas a complementary value to radioiodine scintigraphy in diagnos-
ing metastases from papillary and follicular thyroid cancer [26].
The future role of radiation therapy via sstr in patients with thyroid cancer and dis-
seminated disease remains to be investigated.
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